Recordbate
  • Home
  • Shop
  • Blog
  • Contact us
Search
Login / Register
0 items $ 0
Menu
Recordbate
0 items $ 0
Home Tabroos Tabrophage
SYRINGE 60CC TIP SHIFA
SYRINGE 60CC TIP SHIFA $ 65
Back to products
Tagamet 200mg
Tagamet 200mg $ 45
Click to enlarge

Tabrophage

$ 10

Compare
Add to wishlist
SKU: TABTAB11367 Category: Tabroos
Share:
  • Description
  • Reviews (0)
  • Shipping & Delivery
Description

Tabrecta (Capmatinib) Tablets for Metastatic Non-Small Cell Lung Cancer

Tabrecta is a medication specifically designed for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC). It is indicated for patients whose tumors have a mutation that leads to MET exon 14 skipping, as detected by an FDA-approved test. This mutation results in a protein with a missing regulatory domain, which reduces its negative regulation and leads to increased downstream MET signaling.

How It Works:

Capmatinib, the active ingredient in Tabrecta, is a kinase inhibitor that targets the MET protein, including the mutant variant produced by exon 14 skipping. By inhibiting this protein, Tabrecta helps to reduce the growth and spread of cancer cells.

Dosage and Administration:

The recommended dosage of Tabrecta is 400 mg orally twice daily, with or without food. It is essential to select patients for treatment based on the presence of the MET exon 14 skipping mutation in their tumor specimens.

Important Safety Information:

  • Interstitial Lung Disease (ILD)/Pneumonitis: Monitor for new or worsening pulmonary symptoms indicative of ILD/pneumonitis. Permanently discontinue Tabrecta in patients with ILD/pneumonitis.
  • Hepatotoxicity: Monitor liver function tests regularly. If liver damage occurs, reduce the dose or discontinue the medication.

Product Details:

Tabrecta is available in two strengths: 150 mg and 200 mg. The tablets are ovaloid, curved, and film-coated with beveled edges. The 150 mg tablets are pale orange-brown, while the 200 mg tablets are yellow.

Clinical Benefits:

Tabrecta has shown promising results in clinical trials, with an overall response rate and duration of response that support its use in treating metastatic NSCLC with MET exon 14 skipping mutations. However, continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Tabrophage” Cancel reply

Your email address will not be published. Required fields are marked *

Shipping & Delivery

Related products

Compare
Quick view
Add to wishlist

Cotrim

Tabroos
$ 0
Fenac
Compare
Quick view
Add to wishlist

Fenac

Tabroos
$ 34
Compare
Quick view
Add to wishlist

Rapicort 5 mg

Tabroos
$ 35
Compare
Quick view
Add to wishlist

Rumolon

Tabroos
$ 41
    Recordbate

    Recordbate is a global B2B platform for wholesale medicines, medical equipment, hospital furniture, medical imaging devices and laboratory items

    Need help
    • 410-010-0800
    • info@therecordbate.com
    • 21206 Baltimore, Maryland, United States
    Information
    • Shop
    • Blog
    • About Us
    • Contact us
    Categories
    • Best Selling
    • GlaxoSmithKline
    • Searle
    • Remington
    • Saydon
    • Polyfine
    • Highnoon
    Shop Policies
    • Privacy Policy
    • Terms & Conditions
    Copyright © 2025 Recordbate . All Rights Reserved
    payments
    • Menu
    • Categories
    • Best Selling
    • GlaxoSmithKline
    • Zafa
    • Searle
    • Best Selling
    • GlaxoSmithKline
    • Zafa
    • Searle
    • Wishlist
    • Compare
    • Login / Register
    Shopping cart
    Close
    Sign in
    Close

    Lost your password?

    No account yet?

    Create an Account
    Start typing to see products you are looking for.
    Shop
    Wishlist
    0 items Cart
    My account